Table 1 Patients baseline characteristics (n = 110 and sample characteristics (n = 164).
Gender | Number of patients (percentage) |
|---|---|
Male | 47 (42.7%) |
Female | 63 (57.3%) |
Age, years | |
<55 | 46 (41.8%) |
≥55 | 64 (58.2%) |
Stage (ENETS) | |
I | 32 (29.1%) |
II | 20 (18.2%) |
III | 19 (17.3%) |
IV | 36 (32.7%) |
Unknown | 3 (2.7%) |
Disease Type | |
No residual disease | 66 (60.0%) |
Stable disease | 17 (15.5%) |
Progressive disease | 22 (20.0%) |
Unknown | 5 (4.6%) |
Primary site | |
Pancreatic NET | 48 (43.6%) |
Gastrointestinal NET | 62 (56.4%) |
Primary tumor size, cm | |
<3.0 | 69 (62.7%) |
≥3.0 | 37 (33.7%) |
Unknown | 4 (3.6%) |
Grading (WHO 2010 criteria) | |
G1 | 66 (60%) |
G2 | 34 (30.9%) |
G3 | 4 (3.6%) |
Unknown | 6 (5.5%) |
Adjuvant therapy | |
Somatostatin analogues | 36 (32.7%) |
Interferon | 8 (7.3%) |
Cytotoxic chemotherapy | 5 (4.6%) |
Sunitinib | 1 (0.9%) |
Everolimus | 4 (3.6%) |
Sample characteristics (n = 164) | |
Primary Tumor tissue | 104 (63.4%) |
Metastatic Tumor Tissue | 12 (7.3%) |
Non-tumor adjacent tissues | 48 (29.3%) |
